Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus AgentsSARS-CoV-2 주요 프로테아제의 알로스테릭 결합 부위: 광범위한 항 코로나바이러스 제제의 잠재적 표적Review Published on 2022-08-022022-09-11 Journal: Drug design, development and therapy [Category] SARS, 치료제, [키워드] affected agent allosteric sites Antiviral catalytic activity category caused Characteristics confirmed COVID-19 case COVID-19 COVID-19 disease deaths Disease progression drug target druggability enzyme evaluated explained feasibility Health Organization inhibitor life cycle M pro MPro Mutation pandemic Potential Potential treatment progression reached reported SARS-CoV-2 SARS-CoV-2 virus second Site subsequent target the disease the SARS-CoV-2 the SARS-CoV-2 virus WHO World Health Organization [DOI] 10.2147/DDDT.S370574 PMC 바로가기 [Article Type] Review
Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19COVID-19 치료를 위한 히스타민 H2 수용체 길항제의 용도 변경을 위한 분자 기반Article Published on 2022-08-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] Coronavirus, 신약개발, 유전자 메커니즘, [키워드] activities Analysis antagonist binding affinity carried Cimetidine complex coronavirus COVID-19 determine docking effective Efficacy Famotidine gene target high stability Histamine Ligand mechanism mechanism of action molecular basis molecular docking molecular dynamic simulation molecular dynamics Molecular dynamics simulation Nizatidine non-structural protein non-structural proteins Novel coronavirus Nsp3 Nsp7 Nsp9 Nsps Potential treatment preliminary report Ranitidine Result selected stability targets treat Treatment viral replication was performed [DOI] 10.1080/07391102.2021.1873191 PMC 바로가기 [Article Type] Article
Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19COVID-19로 인한 급성 중증 저산소성 호흡부전에서 폐혈관 확장제의 자비로운 사용Article Published on 2022-08-012022-09-11 Journal: Journal of Intensive Care Medicine [Category] COVID19(2023년), SARS, 신약개발, [키워드] acute hypoxic respiratory failure Adult patients analysed ARDS changes in Cohort cohort of patient collected data commenced COVID-19 death Evidence failure feasible Gradient hospital hypoxaemia hypoxic respiratory failure ICU ICU admission Iloprost implementation Inhaled intensive care intensive care unit lack less median nitric oxide non-survivor Non-survivors offer outcome Oxygenation PaO Patient patients with COVID-19 patients with SARS-CoV-2 PF ratio Potential treatment Primary outcome protocol pulmonary Pulmonary vasodilators. randomised receiving reduction in respiratory Respiratory failure robust severe COVID-19 significantly study period Support survivor the median therapeutic option therapeutic options therapy trials vasodilator [DOI] 10.1177/08850666221086521 PMC 바로가기 [Article Type] Article
Intravenous immunoglobulin: A potential treatment for the post-acute sequelae of SARS-Cov-2 infection?정맥 면역글로불린: SARS-Cov-2 감염의 급성 후유증에 대한 잠재적 치료법?Article Published on 2022-07-292022-09-12 Journal: Bosnian Journal of Basic Medical Sciences [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Potential treatment [DOI] 10.17305/bjbms.2021.6901 PMC 바로가기 [Article Type] Article
Targeting ferroptosis as a vulnerability in pulmonary diseases Reviews Published on 2022-07-262022-10-05 Journal: Cell Death & Disease [Category] 바이오마커, 변종, [키워드] adverse events Asthma degenerative driven by drug-resistant fatty Ferroptosis lipid peroxidation lung cancer Lung diseases Lung injury Numerous Occurrence oxidative oxidative stress Pathogenesis pathology phospholipid PLS Polyunsaturated Potential treatment pulmonary disease pulmonary diseases Pulmonary infection reduce Regulated cell death susceptible targeting [DOI] 10.1038/s41419-022-05070-7 [Article Type] Reviews
Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection Research Published on 2022-07-252022-10-05 Journal: Nature chemical biology [Category] COVID19(2023년), SARS, 변종, 치료법, 치료제, [키워드] alleviate approach can be used cathepsin L Cell CRISPR decrease expression Host host protease in vivo infected with SARS-CoV-2 inhibitor interstitial inflammation knockdown Lower lung Messenger RNA mice mRNA pathological changes Potential treatment Prevent proinflammatory protease reduced reported SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 pathogenesis severity survival treat Treatment unique virus [DOI] 10.1038/s41589-022-01094-4 [Article Type] Research
COVID-19 related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement최근 면역 불활화 바이러스 백신을 접종하고 폐 침범이 없는 환자에서 매우 높은 인터루킨-6 및 RANBP2 돌연변이를 갖는 COVID-19 관련 급성 괴사성 뇌병증Case Reports Published on 2022-07-232022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] Acute kidney injury Acute necrotizing encephalopathy ADE affecting alteration Analysis antibody blood pressure blood-brain barrier body temperature bpm Brain caused Celsius characteristic Chest Chest radiograph Clinical course Coma Computerized tomography consciousness COVID-19 COVID-19 vaccine cytokine cytokine signaling Cytokine storm Cytokines delta variant Encephalopathy examination Factor gene analysis heart rate hemorrhage hepatic failure heterozygous Hypothesis IL-6 immune response immunized inactivated Inactivated vaccine incidence of COVID-19 infiltration interleukin-6 lesion minute Missense mutation mitochondrial Mitochondrial function Mutation Necrosis oxygen oxygen saturation Pathogenesis Patient Potential treatment predictor preserved Previous studies Prognostic factor pulmonary disease pulmonary involvement pyelonephritis Ranbp2 RANBP2. reported respiratory respiratory rate role SARS-CoV-2 SARS-CoV2 infection Seizure Septic shock Sequencing Serum IL-6 Sinopharm Stupor Vaccine viral entry virus whole genome Whole genome sequencing [DOI] 10.1186/s12879-022-07610-0 PMC 바로가기 [Article Type] Case Reports
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, [키워드] Adverse adverse event adverse events Antiviral Antiviral agents clinical Combination combination regimen combination therapy COVID-19 Day demonstrated Efficacy Efficacy and safety event examined Favipiravir FVP group groups hospital ICU admission ill patient in-hospital mortality incidence interferon Interferon-beta IQR LOS median Mild not different not significantly different Patient Potential treatment primary endpoint randomization Randomized randomized clinical trial Randomly receive Registered registry SARS-coronavirus SARS-CoV-2 Seven single-center Treatment treatment regimen Trial viral clearance [DOI] 10.1002/jmv.27724 PMC 바로가기 [Article Type] Randomized Controlled Trial
More questions than answers for the use of inhaled nitric oxide in COVID-19Review article Published on 2022-07-012022-10-05 Journal: Nitric oxide : biology and chemistry [Category] 바이오마커, 임상, 치료제, [키워드] acute respiratory distress administration anti-inflammatory actions antiviral properties approved ARDS bloodstream clinical outcomes Cohort studies coronavirus disease COVID-19 Factor Hypoxemia IMPROVE improvements in oxygenation inactivation Inhaled lung mechanisms Neonates nitric oxide off-label Oxygenation pathological conditions patient selection patients with COVID-19 Potential treatment pulmonary hypertension question Randomized Randomized controlled trial Respiratory failure retrospective SARS-CoV-2 syndrome systemic effect therapy translated Treatment variety Vascular Ventilated [DOI] 10.1016/j.niox.2022.05.001 [Article Type] Review article
The naturally-derived alkaloids as a potential treatment for COVID-19: A scoping reviewCOVID-19의 잠재적 치료제로서의 천연 유래 알칼로이드: 범위 검토Review Published on 2022-07-012022-09-11 Journal: Phytotherapy research : PTR [Category] COVID19(2023년), SARS, 치료제, [키워드] activities acute respiratory syndrome coronavirus alkaloids Anti-inflammatory Antiviral applicability assessments berberine binding energy caused cephaeline clinical trial clinical trials Colchicine coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 database described Effects eligible Emetine Ergotamine high mortality rate homoharringtonine in silico in vitro Inflammatory marker inflammatory markers inhibit knowledge lycorine medicinal plant narciclasine natural product new treatment strategy observational studies papaverine pharmacological plant Potential treatment Protein target protein targets Quinine reduce respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 target proteins Therapeutic compounds Transmissibility treating COVID-19 variety was performed [DOI] 10.1002/ptr.7442 PMC 바로가기 [Article Type] Review